Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases

Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases

Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases

Our Mission

Autoimmune diseases place a staggering toll on our healthcare system and on the lives of patients living with these serious chronic diseases. There are more than 100 different autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn’s disease, and ulcerative colitis.

There is no cure for autoimmune diseases. Currently, available therapies attempt to manage disease symptoms, often relying on immunosuppressive medications that globally dampen immune responses and are burdened with many side effects, which is particularly challenging given the chronic nature of these diseases.

RegCell’s goal is to fundamentally change the way we treat autoimmune diseases by offering therapies that don’t simply address symptoms but provide function and balance to the immune system by restoring long-term immune tolerance in patients with autoimmunity. Our approach is based on the enormous body of work of our scientific founder, Dr. Shimon Sakaguchi.

Dr Sakaguchi is credited with discovering regulatory T cells (Treg) and characterization of their role in maintaining immune tolerance and preventing autoimmune diseases. He has worked extensively to translate this discovery into a therapeutic platform. RegCell’s mission is to utilize this platform to deliver life-changing cell therapies to redefine self-tolerance in patients with autoimmune diseases.

Our Mission

Autoimmune diseases place a staggering toll on our healthcare system and on the lives of patients living with these serious chronic diseases. There are more than 100 different autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn’s disease, and ulcerative colitis.

There is no cure for autoimmune diseases. Currently, available therapies attempt to manage disease symptoms, often relying on immunosuppressive medications that globally dampen immune responses and are burdened with many side effects, which is particularly challenging given the chronic nature of these diseases.

RegCell’s goal is to fundamentally change the way we treat autoimmune diseases by offering therapies that don’t simply address symptoms but provide function and balance to the immune system by restoring long-term immune tolerance in patients with autoimmunity. Our approach is based on the enormous body of work of our scientific founder, Dr. Shimon Sakaguchi.

Dr Sakaguchi is credited with discovering regulatory T cells (Treg) and characterization of their role in maintaining immune tolerance and preventing autoimmune diseases. He has worked extensively to translate this discovery into a therapeutic platform. RegCell’s mission is to utilize this platform to deliver life-changing cell therapies to redefine self-tolerance in patients with autoimmune diseases.

Leadership

Michael McCullar, PhD

Chief Executive Officer

Mike has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades.

James Ahlers

Chief Financial Officer

James is an accomplished leader with over 30 years of experience building life science businesses.

Marty Giedlin, PhD

Chief Technology Officer

Marty is a seasoned immunologist with over 20 years of expertise in recombinant protein, cell and gene therapies and vaccine development.

Tony Hurley

Chief Technical Operations Officer

Tony brings over 30 years of extensive pharmaceutical experience in technical operations with a focus on cell therapy, biologics manufacturing and aseptic processing.

Board of Directors

Steve Kanner, PhD

Dr Kanner currently serves as the chief scientific officer of Caribou Biosciences, Inc (Nasdaq: CRBU) a clinical-stage biotechnology company developing allogeneic cell therapies based on their CRISPR genome-editing technology.

Michael McCullar, PhD

CEO RegCell, Inc.

Mike has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades.

Shuh Narumiya, MD PhD

Dr. Narumiya is Professor and Former Chair of the Department of Drug Discovery Medicine, and the Director of the Medical Innovation Centre at Kyoto University Graduate School of Medicine.

Shimon Sakaguchi, MD, PhD

Dr. Sakaguchi is a Distinguished Professor of Osaka University and a member of the US National Academy of Sciences.

Atsushi Usami, PhD

Dr. Usami is a Partner and Board Director at UTEC, where he leads venture investments and provides hands-on support to seed and early-stage startups, with a primary focus on the life sciences sector.

Koji Yasuda, PhD, DVM

Dr Yasuda is a principal with Fast Track Initiative (“FTI”).

Latest Press Releases & News